


THE VEEDA NEWSLETTER



**Raising Awareness,
Advancing Myeloma
Care**

This Multiple Myeloma Awareness Month, let's amplify conversations, support breakthroughs, and drive meaningful change in treatment and patient outcomes.

Inside Veeda Group: February 2025

From the CEO's Desk

Veeda Voice

Industry Insider

Employee Spotlight

 info@veedalifesciences.com

 www.veedalifesciences.com



**Excellence
In Everything**

From the CEO's DESK



At Veeda Lifesciences, science is more than just research-it is about making a real difference in patients' lives.

As we observe Multiple Myeloma Awareness Month this March, I reflect on how far we have come in the fight against this challenging disease. The advancements in monoclonal antibodies, bispecific T-cell engagers, ADCs, proteasome inhibitors & immunomodulatory drugs are bringing new hope to patients and families worldwide.

At Veeda, we are privileged to contribute to this progress by supporting the development of innovative therapies. Our expertise in disease heterogeneity and MRD (minimal residual disease) assessment helps design trials that are not only scientifically robust but also patient-centric. By integrating AI-driven analytics & real-time data insights, we aim to accelerate patient recruitment & trial efficiency, ensuring that life-saving treatments reach those in need faster.

Ultimately, science is about people-the patients, researchers & healthcare professionals who dedicate themselves to improving lives. I am deeply grateful to our team and partners for their unwavering commitment, and I look forward to continuing this journey of innovation together.


Best Regards,
Dr. Mahesh Bhalgat
Group CEO & MD, Veeda Lifesciences



info@veedalifesciences.com



www.veedalifesciences.com



Ferric Carboxymaltose (FCM): Bioequivalence - Validated Strategies Driving Global Regulatory Success

Veeda Lifesciences: Expertise That Builds Trust with Global Clients

Direct
Regulatory
Engagement:
USFDA & EMA

Study Portfolio:
5 Healthy Volunteer
Studies and 3 Patient
PK Studies and
>30 Feasibilities

Proven
Enrolment
Capacity: 40-
Volunteers &
300+ Patients

Advancing Ferric Carboxymaltose Research with Regulatory Precision

With USFDA's latest guidelines, Veeda Lifesciences is driving innovation in study designs, optimizing drug development while prioritizing patient safety.




Dr. Kiran's Insightful Talk on Safety in Phase 1 Studies

Speaking at a prestigious regulatory workshop, Dr. Kiran Marthak highlighted Veeda's commitment to upholding global research standards in early-phase clinical trials.

ADVANCING CLINICAL BIOANALYSIS WITH PRECISION AND COMPLIANCE


Inside Veeda Biopharma's Clinical Bioanalysis Lab

Watch how we support biotherapeutics and vaccine development with specialized bioanalytical solutions, regulatory expertise, and advanced methodologies.



GCP Training Milestone at Veeda

820+ employees completed a 3-day GCP training led by Dr. Mira Desai, reinforcing regulatory compliance in clinical research.



India Live National Conference highlights imaging & AI-driven tools transforming cardiac management

As cardiovascular diseases (CVD) continue to rise in India, the demand for innovative solutions in interventional cardiology is growing. The 14th India Live National Conference, held from March 21-23, 2025...

[Read More](#)

AdjuTec Pharma & Venus Remedies initiate research collaboration to evaluate APC-148 against AMR

AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, announces that it has entered into a research collaboration agreement with Venus Remedies Limited (India)...

[Read More](#)

Privo Technologies launches BeneVet Oncology, a new subsidiary to improve health of companion animals

Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, announced the launch of BeneVet Oncology...

[Read More](#)

Avatar Medical's brAIIn SPS Secures 510(k) Clearance for Exclusive Use by FX Shoulder Solutions

A cutting-edge, AI-powered and cloud-based surgery solution, brAIIn SPS was developed through a collaboration between Avatar Medical and FX Shoulder Solutions...

[Read More](#)

Apollo Hospitals in Hyderabad becomes India's first AHA-certified comprehensive stroke centre

Apollo Hospitals Hyderabad has become India's first to receive the American Heart Association's highest Comprehensive Stroke Centre (CSC) certification. This recognition highlights its excellence in emergency response...

[Read More](#)

Innovent

Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer

Innovent Biologics announces the successful dosing of the first participant in its Phase 3 trial (HeriCare-Ovarian01) for IBI354 (HER2 ADC), targeting platinum-resistant ovarian cancer with HER2 expression...

Read More



基石药业
CSTONE
PHARMACEUTICALS

CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer

CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab...

Read More



YAQRIT
the liver disease company

Yaqrit secures £2.2 million clinical research grant from NIHR for pivotal trials of its liver support device, Dialive

Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver diseases, announced a major £2.2 million clinical research grant that will fund the development of its extracorporeal liver support device...

Read More



AstraZeneca



AstraZeneca to invest \$2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing

AstraZeneca announced an investment of \$2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance life sciences in China...

Read More



HARBOUR
BIOMED

Harbour BioMed inks collaboration with AstraZeneca to discover & develop next-generation therapeutic antibodies

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in immunology and oncology...

Read More



info@veedalifesciences.com



www.veedalifesciences.com

Employee SPOTLIGHT



Nurturing Future Leaders with V-NAYAC

Veeda's flagship Management Development Program successfully wrapped up its 6-month journey, fostering growth and leadership.

[Read More!](#)



Veeda Expert's Contribution to Insulin Research

Dr. Hiren Mehta co-authored a study on Insulin Aspart, highlighting its faster absorption and impact on biosimilarity.

[Read More!](#)



Celebrating Women's Day at Veeda

A vibrant International Women's Day 2025 at Veeda, honouring the spirit and contributions of our women colleagues.

[Read More!](#)



info@veedalifesciences.com



www.veedalifesciences.com

Contact Us



Corporate Office

VEEDA CLINICAL RESEARCH LIMITED
Satyamev House, Nr. Shalin Bunglow,
Prahladnagar, Ahmedabad 380015

Registered Office

Shivalik Plaza-A, Near IIM Ambawadi,
Ahmedabad- 380015, Gujarat, India.
CIN No. U73100GJ2004PTC044023

Global Offices

- India
- Greece
- Italy
- Ireland



Disclaimer: "The information compiled and published in this newsletter has been sourced, collected and derived from various resources which are in the public domain available on the web & relevant sites. Veeda makes no claims, promises or guarantees about the accuracy, completeness, or adequacy of the contents of the newsletters & expressly disclaims liability for errors & omissions in the contents of this newsletter. The intent and object of this Newsletter is to only disseminate scientific information for knowledge up-gradation. The transmission or reproduction of any items covered in this newsletter beyond that allowed by fair use as defined in the copyright laws may require the written permission of the copyright owners, if any. Neither Veeda, nor its employees & contractors make any warranty, expressed or implied or statutory, including but not limited to the warranties of non-infringement of third party rights, title & the warranties of merchantability and fitness for a particular purpose with respect to content available from the newsletters. This is not a service by Veeda Clinical Research and it does not hold any responsibility for the accuracy of the news/ information provided herein."

 info@veedalifesciences.com

 www.veedalifesciences.com



Excellence
In Everything